- Home
- LPTX vs MYO Comparison
LPTX vs MYO Comparison
Compare LPTX & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- MYO
- Stock Information
- Founded
- LPTX 2011
- MYO 2004
- Country
- LPTX United States
- MYO United States
- Employees
- LPTX N/A
- MYO N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- MYO Industrial Specialties
- Sector
- LPTX Health Care
- MYO Health Care
- Exchange
- LPTX Nasdaq
- MYO Nasdaq
- Market Cap
- LPTX 35.4M
- MYO 36.5M
- IPO Year
- LPTX N/A
- MYO 2017
- Fundamental
- Price
- LPTX $0.42
- MYO $0.88
- Analyst Decision
- LPTX Hold
- MYO Strong Buy
- Analyst Count
- LPTX 1
- MYO 3
- Target Price
- LPTX N/A
- MYO $7.83
- AVG Volume (30 Days)
- LPTX 7.1M
- MYO 2.1M
- Earning Date
- LPTX 11-13-2025
- MYO 11-07-2025
- Dividend Yield
- LPTX N/A
- MYO N/A
- EPS Growth
- LPTX N/A
- MYO N/A
- EPS
- LPTX N/A
- MYO N/A
- Revenue
- LPTX N/A
- MYO $40,760,091.00
- Revenue This Year
- LPTX N/A
- MYO $24.69
- Revenue Next Year
- LPTX N/A
- MYO $20.91
- P/E Ratio
- LPTX N/A
- MYO N/A
- Revenue Growth
- LPTX N/A
- MYO 93.08
- 52 Week Low
- LPTX $0.22
- MYO $0.80
- 52 Week High
- LPTX $4.24
- MYO $7.17
- Technical
- Relative Strength Index (RSI)
- LPTX 42.80
- MYO 36.21
- Support Level
- LPTX $0.43
- MYO $1.04
- Resistance Level
- LPTX $0.56
- MYO $1.13
- Average True Range (ATR)
- LPTX 0.06
- MYO 0.08
- MACD
- LPTX -0.02
- MYO -0.02
- Stochastic Oscillator
- LPTX 0.04
- MYO 0.82
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).